Regulatory Roundup: FDA and Georgetown University Form Innovation Partnership - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA and Georgetown University Form Innovation Partnership

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA and Georgetown University Medical Center have entered a partnership to stimulate innovation in regulatory science, ethics, education, and training, according to a Feb. 24, 2011, agency press announcement. Joint activities will include: research and public-health activities in areas such as novel technologies, public health preparedness, ethics, and bioinformatics; mentorship of doctoral and postdoctoral students in collaborative research relevant to FDA’s mission; scientific staff exchanges and professional-development opportunities, including selected FDA staff serving as adjunct faculty in teaching and clinical activities at Georgetown and selected Georgetown staff participating in research and other activities with FDA; and shared access to and development of important training and continuing education activities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here